Here, potential additional treatment options for patients with MDM2-amplified esophageal adenocarcinoma could be described, for example, the inhibition of CTL2 or MEK with Trametinib, which is currently under investigation as an antitumoral treatment agent. Here, MDM2 is linked to esophageal adenocarcinoma.